SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:liu-119921"
 

Sökning: id:"swepub:oai:DiVA.org:liu-119921" > Treatment of Severe...

Treatment of Severe Renal Disease in ANCA Positive and Negative Small Vessel Vasculitis with Rituximab.

Shah, Shivani (författare)
Department of Medicine, Johns Hopkins University, Baltimore, Md., USA.
Hruskova, Zdenka (författare)
Department of Nephrology, Charles University, Prague , Czech
Segelmark, Mårten (författare)
Linköpings universitet,Avdelningen för läkemedelsforskning,Medicinska fakulteten,Region Östergötland, Njurmedicinska kliniken US
visa fler...
Morgan, Matthew D (författare)
University of Birmingham
Hogan, Jonathan (författare)
Department of Medicine, Hospital of the
Lee, Steven K (författare)
Department of Medicine, Johns Hopkins University, Baltimore, Md
Dale, Jessica (författare)
School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham
Harper, Lorraine (författare)
University of Birmingham
Tesar, Vladimir (författare)
Department of Nephrology, Charles University, Prague , Czech
Jayne, David R W (författare)
Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, Cambridge , UK
Geetha, Duvuru (författare)
Department of Medicine, Johns Hopkins University, Baltimore, Md
visa färre...
Department of Medicine, Johns Hopkins University, Baltimore, Md, USA. Department of Nephrology, Charles University, Prague , Czech (creator_code:org_t)
2015-06-02
2015
Engelska.
Ingår i: American Journal of Nephrology. - : S. Karger. - 0250-8095 .- 1421-9670. ; 41:4-5, s. 296-301
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • BACKGROUND/AIMS: Rituximab and glucocorticoids are a non-inferior alternative to cyclophosphamide and glucocorticoid therapy for induction of remission in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) patients with moderate renal disease. The efficacy and safety of this approach in patients with severe renal impairment are unknown. We report the outcomes and safety profile of rituximab and glucocorticoid therapy for induction of remission in patients with AAV and ANCA-negative vasculitis presenting with severe renal disease.METHODS: A multicenter, retrospective, cohort study was conducted between 2005 and 2014. Patients with new or relapsing disease with an estimated glomerular filtration rate (eGFR) of ≤20 ml/min/1.73 m(2) treated with rituximab and glucocorticoid induction with or without plasmapheresis were included. Fourteen patients met the inclusion criteria. The primary outcomes were rate of remission and dialysis independence at 6 months. The secondary outcomes were eGFR at 6 months, end-stage renal disease (ESRD), survival rates and adverse events.RESULTS: All patients were Caucasian, and 57% were male. The mean eGFR was 12 ml/min/1.73 m(2) at diagnosis. All patients achieved remission with a median time to remission of 55 days. Seven patients required dialysis at presentation of which 5 patients recovered renal function and discontinued dialysis by 6-month follow-up. The mean eGFR for the 11 patients without ESRD who completed 6-month follow-up was 33 ml/min/1.73 m(2). Four patients ultimately developed ESRD, and one died during the follow-up period.CONCLUSION: Patients with AAV and severe renal disease achieve high rates of remission and dialysis independence when treated with rituximab and glucocorticoids without cyclophosphamide. © 2015 S. Karger AG, Basel.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Urology and Nephrology (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy